Vir Biotechnology Inc. (NASDAQ:VIR) reported better-than-expected fourth-quarter earnings, anounced a significant strategic collaboration with Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY), and also disclosed early study results for VIR-5500.
Vir Biotechnology reported a fourth-quarter loss of 31 cents, beating the consensus loss of 41 cents. Sales reached $64.07 million, surpassing the consensus of $23.18 million.
The partnership with the Japanese drugmaker announced on Monday aims to advance VIR-5500, an investigational treatment for prostate cancer, which is expected to enhance the company’s …